期刊文献+

白细胞介素7基因转染口腔癌细胞株的免疫调节效应的研究 被引量:2

Study on the effect of immune regulation of interleuk-7 (IL-7) gene transfected into human tongue squamous carcinoma cell lines
下载PDF
导出
摘要 目的:探讨IL-7基因转染人舌鳞癌Tca8113细胞株的免疫调节效应。方法:将已构建的原核/真核表达载体pBK-CMV/IL-7转染到癌细胞株中,采用MTT法检测转染前后肿瘤细胞培养上清对鼠脾细胞增殖的影响;ELISA法检测细胞培养上清转移生长因子β1(TGF-β1)、血管内皮生长因子(VEGF)和IL-10的浓度。将pPK-CMV/IL-7癌细胞株移植于小鼠腹腔,观察肿瘤细胞的成瘤性;并采用MTT法检测其NK杀伤活性。结果:IL-7基因转染癌细胞株的培养上清对鼠脾细胞的增殖抑制作用与对照组比较显著下降(P<0.05),并且IL-7基因转染的肿瘤细胞产生TGF-β1、VEGF和IL-10三种免疫抑制因子明显降低(P<0.05);IL-7基因转染组鼠腹腔瘤结节明显小于对照组(P<0.05);NK的杀伤活性与对照组比较,具统计学差异(P<0.05)。结论:IL-7基因转染人舌鳞癌细胞株具有抑瘤作用,其机理可能是通过降低肿瘤细胞产生免疫抑制因子,进而促进淋巴细胞增殖,提高NK的杀伤活性。 AIM: To investigate the effect of immune regulation of IL-7 gene transfected into human carcinoma line Tca8113. METHODS: pBK-CMV/IL-7 plasmid was transfected into human tongue squamous carcinoma cell lines. The effect of the supernatant of carcinoma culture on the proliferation of lymphocytes was measured using MTT method. The concentrations of TGF-β1, VEGF and IL-10 were determined by ELISA. Human carcinoma cells lines with pPK-CMV/IL-7 were injected into peritoneal of mice, and the tumor formed in peritoneal was detected. The killing activity of NK was analyzed by MTT. RESULTS: Compared with control group, the supernatant from carcinoma cells culture could significantly suppress the proliferation of lymphocytes (P〈0.05). The supernatant levels of TGF-β1, VEGF and IL-10 were obviously decreased. The tumor volume in experimental group were fewer then those in control group(P〈0.05). The killing activity of NK was significantly increased (P 〈0.05). CONCLUSION: IL-7 gene transfection into human carcinoma line Tea8113 could inhibit tumor growth by reducing secretion of immunosuppressive factors, enhancing lymphocyte proliferation and increasing the killing activity of NK.
出处 《中国临床药理学与治疗学》 CAS CSCD 2010年第3期247-250,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 中国-意大利科技合作项目(200625)
关键词 IL-7 免疫调节 口腔癌细胞株 IL-7 Immune regulation Human tongue squamous carcinoma cell lines
  • 相关文献

参考文献10

  • 1Li X,Ye F, Chen H, et al. Human ovaria carcinoma cells generates CD4 (+) CD25 ( + ) regulatory T cell from peripheral CD4 (+)CD25 (-) T cell through secreting TGF-beta [J]. Cancer Letter, 2007,253(1) :144-153.
  • 2Kim ES, Kim MS, Moon A. Transforming growth factor(TGF-beta) in conjunction with H-ras activation promotes malignant progression of MCF10A Cytokine, 2005,29(2) : 84.
  • 3Andersson A, Yang SC, Huang M, et al. IL-7 promotes CXCR3 ligand-dependt T cell antitumor reactiveity in lung cancer[J]. J Immunol, 2009, 182 (11) :6951-6958.
  • 4谢强,蒋志文,祝晓光,刘浩.HSPG和无HS-GAGs链HSPG体外抗乳腺癌的研究[J].中国临床药理学与治疗学,2009,14(6):617-623. 被引量:2
  • 5Lynch DH, Miller RE. Interleukin 7 promotes long-term in vitro groth of antitumor cytotoxic T lymphoeytes with immunotherapeutic efficacy in vivo[J]. J Exp Med, 1994,179:32-42.
  • 6Geiselhart LA, Humphries CA, Gregorio TA, et al. IL-7 administration alters the CD4:CD8 ratio, increase T cell number, and increase T cell function in the absence of activation[J]. J Immunol, 2001, 166(5) :3019-3027.
  • 7Krawczenko A, Kieda C, Dus D. The biological role and potential therapeutic application of IL-7 [J]. Arch Immunol Ther Exp, 2005,53(6):518-525.
  • 8Lezzi G, Piattelli A, Rubini C, et al. Expression of transforming growth factor beta1 in a ameloblastomas[J]. J Craniofac Surg, 2008,19(6):1618- 1621.
  • 9Yanagawa Y, Iwabuchi K, Onoe K. Co-operative action of interleukin-10 and interferon-gama to regulate dendritic cell function[J]. Immunology, 2009, 127(3) :345-353.
  • 10Chung EK, Stadler WM. Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer [J]. Clin Genitourin Cancer, 2008,6 ( 1 ):S22 -S28.

二级参考文献22

  • 1姜笃银,付小兵,盛志勇.硫酸乙酰肝素糖蛋白的结构-功能多样性与相关修饰酶群作用[J].中国病理生理杂志,2005,21(5):1020-1025. 被引量:7
  • 2Bloushtain N, Qimron U, Bar-Ilan A. Membrane-associated hepran sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46[J]. J Immtmol, 2004,173(4) :2392- 2401.
  • 3张均田.现代药理实验方法[M].北京医科大学中国协和医科大学联合出版社,1998:819-820.
  • 4Hiroko H , Koji K. Heparan sulfate proteoglycans mediating the epithelial and mesenchymal interaction[ J ]. Seikagaku, 2001,73(10) : 1246 - 1256.
  • 5Mali M, Elenius K, Miettinen HM, et al. Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1[J]. J Biol Chem, 1993,268 (32) :24215 - 24222.
  • 6Dhodapkar MV, Abe E, Theus A, et al. Syndecan21 is a muhifunctional regulator of myeloma pathobiology : Control of tumor cell survival, growth, and bone cell differentiation[J]. Blood, 1998,91(8) :2679- 2688.
  • 7Gonzalez AD, Kaya M, Shi W, et al. OCI25/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmelovergrowth syndrome, induces apoptosis in a cell line-specificmanner[J]. J Cell Biol, 1998, 141(6): 1407- 1414.
  • 8Schmidt A, Yoshidall K. The antiproliferative activity of arterial heparan sulfate resides in domains enriched with 2- 0-sulfated uronic acid residue[J]. J Cell Biol, 1992,267: (27), 19242 - 19247.
  • 9Perrimon N, Bernfield M. Specificities of heparan sulphate proteoglycans in developmental processes [ J ]. Nature, 2000,404(6779) :725 - 728.
  • 10Gilat D, Hershkoviz R, Golakom I, et al. Moleuclar behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH [ J]. J Exp Med, 1995,181(5) : 1929 - 1934.

共引文献1

同被引文献26

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部